stockrow
Friday 6 November 2026
Export PCVX’s income statement to Excel — free account
Vaxcyte, Inc.
PCVX Healthcare Biotechnology
- EPS
- −61.5%
- Free cash flow
- −92.6%
Quarter to June 2026, against a year earlier
63.82
1.90
+3.07%
Follow PCVX
Alert me
Vaxcyte, Inc. (PCVX) Net income
Vaxcyte, Inc.'s net income for fiscal 2025 was −$766.6M, compared with −$463.9M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$1.1B. Over the past ten years it has ranged from −$766.6M (fiscal 2025) to $0.00 (fiscal 2017) — the current reading is the lowest in ten years. Net income has fallen for 8 consecutive fiscal years. Vaxcyte, Inc. ranks 602nd of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$766.6M | — |
| FY2024 | −$463.9M | — |
| FY2023 | −$402.3M | — |
| FY2022 | −$223.5M | — |
| FY2021 | −$100.1M | — |
| FY2020 | −$89.2M | — |
| FY2019 | −$50.3M | — |
| FY2018 | −$29.5M | — |
| FY2017 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$284.3M | — |
| Mar 2026 | −$320.6M | — |
| Dec 2025 | −$246.5M | — |
| Sep 2025 | −$212.8M | — |
| 26 more quarters | Free account |
Against its own ten years
Low −$766.6M
High $0.00
Ten-year median
−$100.1M
Current reading's percentile
11
Net income against peers
| Company | Net income |
|---|---|
| TGTX TG Therapeutics, Inc. compare | $441.5M |
| TECH Bio-Techne Corp compare | $181.9M |
| CAI Caris Life Sciences,�Inc. compare | $96.1M |
| PTGX Protagonist Therapeutics, Inc. compare | $82.9M |
| BMRN BioMarin Pharmaceutical Inc. compare | −$19.1M |
| TWST Twist Bioscience Corporation compare | −$136.7M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$155.5M |
| IBRX ImmunityBio, Inc. compare | −$992.4M |
| PCVX Vaxcyte, Inc. | −$1.1B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item